IFN-α（Interferon-alpha，IFN-Alpha）是指干擾素α，它是一種類型的細(xì)胞因子，屬于干擾素家族。干擾素是哺乳動(dòng)物細(xì)胞因子家族，具有調(diào)節(jié)免疫反應(yīng)和抗病毒能力的作用。它們由大多數(shù)細(xì)胞類型合成和分泌，以響應(yīng)病原體。除了抗病毒特性外，干擾素還被證明具有抗增殖、免疫調(diào)節(jié)和許多其他活性。  

  在人類中，IFN-α由一組氨基酸序列同源性大于85%的蛋白質(zhì)組成。已鑒定出許多個(gè)人類IFN-α亞型；許多顯示不同的屬性。目前尚不清楚為什么有多種IFN-α亞型。各種研究表明，它們具有重疊但又獨(dú)特的生物活性。 我們推薦高靈敏度的人IFN-α全亞型ELISA試劑盒旨在對(duì)自身免疫血清、正常血清、EDTA 血漿和組織培養(yǎng)基（TCM）中的所有人IFN-α亞型進(jìn)行準(zhǔn)確的低 pg/ml 測(cè)量。提供了一種可靠且靈敏的方法，因此對(duì)于免疫學(xué)、炎癥和治療藥物監(jiān)測(cè)方面的研究非常有價(jià)值。作為PBL Assay Science在中國(guó)區(qū)域的代理商，艾美捷科技將為中國(guó)客戶提供全面的PBL Assay Science產(chǎn)品以及客戶訂制化服務(wù)。歡迎大家隨時(shí)聯(lián)系我們。  

引用文獻(xiàn)（Citations）：

1. Ou, B.S. et al., (2024), "Nanoparticle-Conjugated Toll-Like Receptor 9 Agonists Improve the Potency, Durability, and Breadth of COVID-19 Vaccines", ACS NanoDOI: 10.1021/acsnano.3c09700

2. Biava, M. et al., (2023), "In Vitro and In Vivo Crosstalk between Type I IFN and IL-8 Responses in SARS-CoV-2 Infection", Microorganisms, 11(11):2787, PMID: 38004798, DOI: 10.3390/microorganisms11112787

3. Grunhagel, B., et al., (2023), "Reduction of IFN-I Responses by Plasmacytoid Dendritic Cells in a Longitudinal Trans Men Cohort, iScience, DOI: 10.1016/j.isci.2023.108209

4. Nagaoka, K. et al., (2023), "Dominant CT Patterns and Immune Responses during the Early Infection Phases of Different SARS-CoV-2 Variants", Viruses, 15:1304, DOI: 10.3390/v15061304

5. Kida, Y. et al., (2023), "Lethal Interstitial Lung Disease Associated with a Gain-of-Function Mutation in IFIH1",  Clin Immunol., PMID: 37126154, DOI: 10.1007/s10875-023-01494-8

6. Kim, S.T. et al., (2023). "Interferon and interferon-induced cytokines as markers of impending clinical progression in ANA+ individuals without a systemic autoimmune rheumatic disease diagnosis", Arthritis Res. Ther., PMID: 36765391, DOI: 10.1186/s13075-023-02997-w

7. Bibby, J.A., et al., (2022), "Systematic single-cell pathway analysis to characterize early T cell activation, Cell Rep., 41(8):111697, PMID: 36417885, DOI: 10.1016/j.cellrep.2022.111697

8. Rajamanickam, A. et al., (2022), "Restoration of dendritic cell homeostasis and Type I/Type III interferon levels in convalescent COVID-19 individuals, BMC Immunol., 23(1):51, PMID: 36289478, DOI: 10.1186/s12865-022-00526-z

9. Kubo, S. et al., (2022), "Lactoferrin and its digestive peptides induce interferon-a production and activate plasmacytoid dendritic cells ex vivo", Biometals, PMID: 36018422, DOI: 10.1007/s10534-022-00436-y

10. Nagaoka, N., et al., (2022), "Effect of Casirivimab/Imdevimab Treatment on Serum Type I Interferon Levels in SARS-CoV-2 Infection", Viruses, 14(7):1399, DOI: 10.3390/v14071399

11. Edahiro, Y., Ohishi, K., Gotoh, A. et al., (2022),  "Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study",  J. Hematol., PMID: 35430707, DOI: 10.1007/s12185-022-03341-9 

12. Kanazawa, N. et al.,(2021), Heterozygous missense variant of the proteasome subunit β-type 9 causes neonatal-onset autoinflammation and immunodeficiency, Nature Communications, 12:6819, DOI: 10.1038/s41467-021-27085-y

13. Jablonska, A., et al.,  (2021), The TLR92848C/T Polymorphism Is Associated with the CMV DNAemia among HIV/CMV Co-Infected Patients, Cells, 10:2360, DOI: 10.3390/cells10092360,

14. Peluso, Michael, et al.(2020). Liver function test abnormalities in a longitudinal cohort of Thai individuals treated since acute HIV infection. PLOS Pathogens, 9 pgs. PMID: 31953919.

15. Dagenais-Lussier, Xavier, et al.(2019). USP18 is a significant driver of memory CD4 T-cell reduced viability caused by type I IFN signaling during primary HIV-1 infection. PLOS Pathogens, 32 pgs. PMID: 31658294.

16. Colavita, Francesca, et al.(2018). Overproduction of IL-6 and Type-I IFN in a Lethal Case of Chikungunya Virus Infection in an Elderly Man During the 2017 Italian Outbreak. Open Forum Infectious Diseases, 21 pgs. PMID: 30539034.

17. Williams, Dionna, et al.(2018). CCR2 Signaling Selectively Regulates IFN-alpha: Role of Beta-Arrestin 2 in IFNAR1 Internalization. Journal of Immunology, 19 pgs. PMID: 30504423.

18. Zhang, Guoliang, et al.(2018). A Proline Deletion in IFNAR1 Impairs IFN-Signaling and Underlies Increased Resistance to Tuberculosis in Humans. Nature Communications, 9 pgs. PMID: 29311663.

19. Murayama, Goh, et al. (2017). Enhanced IFN-alpha Production is Associated with Increased TLR7 Retention in the Lysosomes of Palasmacytoid Dendritic Cells in Systemic Lupus Erythematosus. Arthritis Research & Therapy, 11 pgs. PMID: 29052537.

20. Wither, Joan, et al. (2017). Presence of an Interferon Signature in Individuals Who are Anti-Nuclear Antibody Positive Lacking a Systemic Autoimmune Rheumatic Disease Diagnosis. Arthritis Research & Therapy, 11 pgs. PMID: 28245862.

21. Vanheule, Vincent, et al. (2016). Basic Chemokine-Derived Glycosaminoglycan Binding Peptides Exert Antiviral Properties Against Dengue Virus Serotype 2, Herpes Simplex Virus-1, and Respiratory Syncytial Virus. Biochemical Pharmacology, 13 pgs. PMID: 26551597.

22. Combes, Alexis, et al. (2020). Global Absence and Targeting of Protective Immune States in Severe COVID-19. Nature, 36 pgs.

看到這兒，您心動(dòng)了嗎？馬上聯(lián)系小艾吧！ 

美國(guó)的PBL Assay Science（又名：Pestka Biomedical Laboratories, Inc.）成立于1990年，創(chuàng)始人Sidney Pestka被稱為“干擾素之父”，PBL Assay Science 作為干擾素和細(xì)胞因子蛋白和抗體以及預(yù)包裝的一流的干擾素和細(xì)胞因子免疫測(cè)定試劑盒的高質(zhì)量制造商而享有盛譽(yù)。生產(chǎn)和銷售的高品質(zhì)干擾素產(chǎn)品和生物標(biāo)志物檢測(cè)試劑盒在很多高影響力出版物中都有引用，并已在具有挑戰(zhàn)性的樣本中進(jìn)行了外部驗(yàn)證。 

PBL Assay Science提供各種干擾素亞型的蛋白，抗體和檢測(cè)試劑盒，如：IFN-Alpha（IFN-ɑ 2a，IFN-ɑ 2b，IFN-ɑ 5，IFN-ɑ 6，IFN-ɑ 7，IFN-ɑ 14，IFN-ɑ 16，IFN-ɑ 17......），IFN-Beta（IFN-β 1a，IFN-β 1b），IFN-Lambda（IFN-λ），IFN-Omega（IFN-ω），IFN-Gamma（IFN-γ）...... 

武漢艾美捷科技有限公司，簡(jiǎn)稱艾美捷，擁有進(jìn)出口資質(zhì)和自己的國(guó)際物流，與國(guó)內(nèi)外90余家知名的試劑、原料及技術(shù)服務(wù)供應(yīng)商深度合作，是國(guó)內(nèi)生物制藥企業(yè)、診斷企業(yè)、跨國(guó)藥企、各大高校院所采購(gòu)平臺(tái)的首選定供應(yīng)商。